This edition presents the views and insights from three of the world's foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the renal cell carcinoma (RCC) market, including: the FDA awarding Priority Review for a new supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab; Merck & Co.) in combination with Inlyta (axitinib; Pfizer) for the first-line treatment of patients with advanced RCC, based on findings from the KEYNOTE-426 trial; the EU approval of Opdivo (nivolumab; Bristol-Myers Squibb [BMS]) in combination with Yervoy (ipilimumab; BMS) for the first-line treatment of patients with intermediate- and poor-risk advanced RCC, based on data from the CheckMate-214 study; updated findings from the CheckMate-214 trial of Opdivo plus low-dose Yervoy presented at ASCO GU 2019.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved